

A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- documented pancreatic adenocarcinoma that is confined to the pancreas and regional lymph nodes - one prior line of therapy is permitted - normal cardiac and pulmonary function - participants with partners of childbearing potential must be willing to use at least two forms of effective birth control - see link to clinicaltrials.gov for complete inclusion & exclusion criteria

Exclusion Criteria:

- women who are pregnant or breastfeeding - other types of pancreatic cancer - history of human immunodeficiency virus (HIV) infection - history of or active acute or chronic active hepatitis B or C infection - taking 10mg/day or more of prednisone for more than one week

Conditions & Interventions

Interventions:

Biological: Replicative Adenovirus Vector (RGDCRAdCOX2F)

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Adenocarcinoma of Pancreas, Pancreatic Cancer

More Information

Description: This is an early study of a new drug, RGDCRAdCOX2F, as a single tumor injection in persons with adenocarcinoma of the pancreas. The main goal of the study is to find a safe dose of the study drug.

Study Contact: Edward Greeno - green048@umn.edu

Principal Investigator: Edward Greeno, M.D.

Phase: PHASE1

IRB

Number: STUDY00021119

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.